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ALICE E. ARNIM-BARKER. Alterations in Myocyte Protein Extractability and 
Composition Accompany the Development of Supraventricular Tachycardia Induced 
Dilated Cardiomyopathy. (Under the direction of FRANCIS G. SPINALE.) 
Chronic pacing supraventricular tachycardia (SVT) in animals causes a dilated 
cardiomyopathy (DCM) similar to the clinical spectrum of congestive heart failure 
observed in humans. However, cellular mechanisms for the changes in left ventricular 
(LV) geometry with SVT -DCM remain unclear. Accordingly , LV and myocyte structure 
and function were examined in 7 pigs with chronic SVT (pace 240 bpm, 3 wks) and in 
7 control pigs. Left ventricular end-diastolic dimension increased (5.3 +0.2* vs 3.8+0.2 
em), and LV fractional shortening (14 + 1 * vs 34 + 1 %) and wall thickness decreased 
(0.49+0.01* vs 0.72+0.03 cm) with SVT (*p<0.05 compared to control). Left 
ventricular isolated myocyte function using computer assisted video-microscopy revealed 
decreased percent shortening (2.6±0.1 * vs 4.9±0.1 %), velocity of shortening (31 + 1 * 
vs 58+1 /lm/s) , and velocity ofrelengthening (32+0.8* vs 63+1.6 /lm/s) with SVT. 
A potential mechanism for these changes in LV and myocyte function and geometry was 
studied by examining myocyte protein extractability, as well as isolated myocyte 
cytoarchitecture. The findings of this study show that with SVT, the percent extractable 
protein per myocyte increased by over 160% compared to controls. This increase in 
extractable protein is correlated to changes in LV geometry (r = 0.39, P = 0.016), and 
is also negatively correlated to myocyte contractile function (r = 0.318, P = 0.036). 
Electrophoretic analysis of myocyte extractable protein revealed an increase in protein 
VIn 
in the 114 and 58 kD ranges, as well as in a very high molecular weight protein. 
Immunofluorescent staining of SVT cardiomyopathic myocytes revealed an altered pattern 
of cytoskeletal staining for O!-tubulin and a thickened weave of t3-tubulin.. These results 
suggest that alterations' in myocyte protein extractability and cytoarchitecture may be 
related to the depressed contractile performance in this form of cardiomyopathic disease. 
Introduction 
The primary functions of the heart are to receive blood from the venous system, 
deliver it to the lungs for subsequent oxygenation, and pump the oxygenated blood to all 
body tissues. Heart failure occurs when these functions are notably disturbed, and is the 
ufinal common pathway" for all serious forms of heart disease. The principal clinical 
indications of heart failure are shortness of breath (dyspnea) and exercise intolerance. 
Heart failure may occur when the heart has borne an excessive burden for a considerable 
time, such as in patients with hypertension, valvular heart disease, and some forms of 
congenital heart disease. The heart may also fail as a result of ischemic heart disease 
and a diversity of infectious, inflammatory, and infiltrative conditions that affect heart 
muscle. 1 
Heart failure is estimated to afflict more than 3 million patients in the United 
States, occurring in 1 % to 2 % of the population, depending on age. Almost 400,000 
people develop heart failure for the first time each year, making heart failure the nation's 
most rapidly growing cardiovascular disorder. Heart failure is a major cause of disability 
and morbidity and is the most common reason for hospitalization of the elderly. This 
disease accounts for up to 5% of general hospital admissions at anyone time, 
approximately 1 million Americans annually, and the United States spends more than $8 
billion in the care of these patients per year. The mortality rate of heart failure is high, 
ranging from 50% in 5 years for patients in a general population, to 50% in 1 year in 
2 
those with advanced heart failure; nearly 200,000 Americans die of heart failure each 
year. 2•3 Two segments of the American population, the elderly and blacks, are 
particularly at risk of developing heart failure. Because these groups comprise a growing 
proportion of the population, the prevalence of heart failure and deaths from this 
condition are anticipated to rise if improved treatments and a method of prevention are 
not developed. 1 
An important etiology of heart failure is dilated cardiomyopathy, which is also a 
significant cause of morbidity and mortality. The prevalence and incidence of dilated 
cardiomyopathy has apparently increased during the past twenty years, although this 
increase may be due to improved case detection. 2,4 Idiopathic dilated cardiomyopathy is 
the primary indication for heart transplantation, with related costs of approximately $177 
million annually. 4 Dilated cardiomyopathy is characterized by cardiac dilatation and 
systolic dysfunction. The commonly accepted criteria for left ventricular (LV) dilation 
include a LV internal diastolic dimension greater than 2.7 cm per m2 of body surface 
area and the common criteria for impaired systolic function include an ejection fraction 
which is decreased to less than 40 to 45 % .4 Chamber enlargement is thought to result 
either from elongation of the myofibrils by addition of sarcomeres longitudinally or by 
slippage of fibers in a remodeling process. In either case, the enlarged chamber will lead 
to an increase in wall stress, which is a physical stimulus to myocardial hypertrophy, and 
to a reduction of global wall motion. This remodeling may be a major determinant of 
the progression of heart failure and its premature mortality. 5 
3 
Activation of neurohormonal systems is a traditional indication of the heart failure 
syndrome. 5 Increased plasma levels of norepinephrine and increased plasma renin 
activity have been identified as poor prognostic factors for patients with dilated 
cardiomyopathy. (Other factors include decreased LV wall thickness and decreased mass 
to volume ratio, while ejection fraction is the most powerful predictor of mortality.)4 
Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry indicated that 
patients with a lower ejection fraction were found to have significantly higher plasma 
norepinephrine and atrial natriuretic peptide levels. 6 Increased plasma levels of 
endothelin, a peptide hormone with potent vasoconstrictor actions, have also been 
reported in patients with heart failure. 7 Therefore, dilated cardiomyopathy is 
characterized by reduced LV pump function, alterations in contractile state, and 
neurohormonal activation. 2-4,6,8 
In order to gain an improved understanding of the development and progression 
of disease states in humans, animal models of diseases have been developed. The report 
of the Task Force on Research in Heart Failure stated that the model of heart failure 
caused by electrical pacing is one of two models that appear to be particularly promising 
for improving understanding of human heart failure (the other model is caused by 
naturally occurring genetic abnormalities).l Chronic supraventricular or ventricular 
tachycardia in animals has been shown to cause LV dilation and dysfunction and 
neurohormonal activation which is similar to the clinical spectrum of cardiomyopathic 
disease. 3,6.8-12 Furthermore, chronic pacing induced supraventricular tachycardia has been 
shown to cause alterations in myofibril ultrastructure which have been associated with 
4 
alterations in myocyte contractile function and geometry. 3.6.8-11.13.14 Therefore, this model 
of dilated cardiomyopathy provides an opportunity to investigate the fundamental 
mechanisms which contribute to the development and progression of cardiomyopathic 
disease. 
The development of chronic tachycardia induced dilated cardiomyopathy causes 
an increase in LV chamber size and no change or a decrease in wall thickness, which in 
tum result in increased wall stress.4.11.12.14.15 Furthermore, the development of LV 
dysfunction due to chronic pacing tachycardia causes increased catecholamine levels, 
increased plasma renin activity, and increased endothelin levels. 16-18 In previous studies 
it has been shown that increased wall stress (physical stimulus) and neurohormonal 
activation (chemical stimulus) cause increased protein synthesis and LV hypertrophy.19 
However, in spite of the increase in LV wall stress and neurohormonal activation with 
the development of tachycardia induced cardiomyopathy, these putative stimuli do not 
cause a significant increase in LV mass (hypertrophy). 
In order to investigate the abnormal function of the heart muscle seen with heart 
failure, normal contractile function must first be understood. The contractile unit of the 
myocyte is the sarcomere, and contained within the contractile apparatus are four 
important constitutive proteins: actin, myosin, tropomyosin, and troponin. The heaviest 
of these contractile proteins is myosin, which is composed of six subunits: two heavy 
chains and four light chains, forming a functional complex of molecular weight 540 
kilodaltons (kD). The second contractile protein, actin, which colocalizes with myosin, 
is a globular protein (42 kD) that exists as a helical structure. Tropomyosin, composed 
5 
of two subunits of 32 kD each, interdigitates with actin and myosin and plays a crucial 
role in acto-myosin crossbridging. The final contractile protein, troponin, is actually a 
protein complex composed of calcium-binding (troponin-C), tropomyosin-binding 
(troponin-T), and actin-binding (troponin-I, inhibitory) components.20 
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Figure 1. A model of the sarcomere, the repeating contractile unit of 
the myocyte. 
filament theory. There are two myofilaments: thick (composed of myosin) and thin 
(composed of actin, tropomyosin, and troponin). Hydrolysis of an ATP molecule 
attached to myosin puts a myosin crossbridge into a high energy configuration. Calcium 
is released from the sarcoplasmic reticulum (SR) after an action potential causes an influx 
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of calcium ions from the transverse tubules of the sarcolemmal membrane. The calcium 
released from the SR binds to troponin-C, causing a conformational change in troponin 
and tropomyosin. This change in conformation unblocks the actin binding site for 
myosin, allowing actin and myosin to interact. The two proteins interact by means of 
the myosin crossbridge head, which attaches to actin and rotates in a matter that causes 
the thick and thin protein filaments to slide past each other. This "power stroke" 
shortens the sarcomere and causes the release of the products of the hydrolyzed A TP. 
Upon binding with another ATP, the myosin head detaches from the actin molecule, a 
process called active relaxation, and the cycle is ready to begin' again. 20.21 
In order for the contractile processes to proceed in a normal fashion, the 
contractile proteins must be properly aligned. Many proteins have been discovered to 
playa role in myofibrillogenesis, the development of myofibrils and their association into 
sarcomeres. Titin (also known as connectin) is a very high molecular weight protein 
(approximately 2-3 MDa) that has recently been determined to be the third most abundant 
component of the sarcomere, comprising about 10% ofmyofihrillar proteins. Titin spans 
from the M line to the Z line of the sarcomere, and is thought to be a member of a third 
filament system, the "gap filament" system. Unique to striated muscle, titin functions 
in the elastic recoil and alignment of the sarcomere. Titin may also play a role in 
filament alignment during sarcomere assembly. 22.23 
Another cytoskeletal protein which may playa role in the assembly of sarcomeres 
is tubulin. Tubulin is a heterodimer which consists of a-tubulin and {3-tubulin; both 
subunits have a molecular weight of approximately 50-55 kD and share considerable 
7 
homology. Tubulin is the main constituent of microtuhules, which are organelles found 
in nearly all eukaryotic cells. 24 Microtubules function in the maintenance of cell 
orientation and cell movement, and are also a major component of the mitotic spindle. 25-27 
In adult cardiac myocytes, however, microtubules are present in small numbers, and may 
not have the range of function in myocytes that they do in other cells. 26 Possible 
functions of microtubules in cardiac myocytes are the transport of proteins and organelles 
throughout the cytoplasm, and a role in sarcomere orientation. 25.28 
Recent studies have concentrated on cellular and intracellular changes that may 
contribute to the alterations of LV function and geometry -which accompany the 
development of supraventricular tachycardia (SVT) induced cardiomyopathy. Myocytes 
isolated from the left ventricle following SVT induced cardiomyopathy were determined 
to be significantly longer than myocytes isolated from control left ventricles. 29,3o SVT 
induced cardiomyopathic myocytes have also been determined to have a significantly 
reduced cross-sectional area. 29.31 Thus, these studies have shown that hypertrophy does 
not occur with the development of SVT cardiomyopathy at the myocyte level, which 
parallels the lack of hypertrophy at the level of the left ventricle. 
Potential changes in myosin heavy chain, one of the major contractile proteins of 
the myocyte sarcomere, have also been investigated. A study performed by Williams et 
al. showed that the levels of mRNA encoding {J-myosin heavy chain did not significantly 
change from baseline values, despite the development of tachycardia induced heart failure 
in dogS. 32 Also, a recent study performed in this laboratory showed that there was no 
change in steady state mRNA levels for myosin heavy chain or a-cardiac actin with the 
8 
development of SVT cardiomyopathy compared to controls. 31 Another recent study 
performed in this laboratory showed that there were no changes in myosin heavy chain 
associated with tachycardia induced cardiomyopathy at the protein level. 33 Therefore, 
the changes in myocyte geometry that accompany the development of SVT induced 
cardiomyopathy are not dependent upon increased amounts of contractile proteins. 
Taken together, the findings from these past studies suggest that with the 
development of tachycardia induced cardiomyopathy, significant intracellular remodeling 
must occur in order to allow for myocyte lengthening with no alteration in absolute 
myosin heavy chain content. One potential mechanism < for the changes in 
cytoarchitecture in this model of dilated cardiomyopathy is alterations in protein assembly 
and/or disassembly with subsequent changes in myocyte protein extractability. 
Accordingly, this study was designed to test the following hypothesis: 
Are the changes in left ventricular myocyte function and geometry which 
occur with the development of chronic pacing induced cardiomyopathy associated 
with concomitant alterations in the composition and extractability of myocyte 
proteins? 
The specific aims for this hypothesis are as follows: 
1. to determine the amount of extractable protein per myocyte with the 
development of supraventricular tachycardia (SVT) induced cardiomyopathy 
9 
2. to determine the relationship between the amount of extractable protein and 
myocyte contractile function 
3. to detennine if any differences exist between the composition of extractable 
protein from control myocytes and from myocytes following the development of 




Fourteen age and weight matched pigs (Yorkshire, 6 months old, average weight 
28 kg) were randomly assigned to two groups: 1) SVT; pacing induced supraventricular 
tachycardia at 240 beats per minute for 3 weeks (n = 7), and 2) sham-operated controls 
(n = 7). The pigs were treated and cared for in accordance with the National Institutes 
of Health "Guide for the Care and Use of Laboratory Animals" (DHEW Publication 
(NIH) 86-23, revised 1985). The pigs were anesthetized with" isoflurane (2.0%, 1.5 
L/min) and nitrous oxide (0.5 L/min) and intubated. Through a left thoracotomy, a 
shielded stimulating electrode was sutured onto the left atrium and connected to a 
programmable pacemaker modified for programming heart rates up to 300 beats per 
minute (Model 8329, Medtronic, Minneapolis, MN), which was placed ina subcutaneous 
pocket. The pericardium was left open, the thoracotomy was closed, and the pleural 
space was evacuated of air. Seven to ten days postoperatively, pacing induced SVT was 
initiated at 240 beats per minute, which was selected because it is twice the normal heart 
rate for pigs. Cardiac auscultation was performed and electrocardiograms obtained 
frequently during the pacing protocol to ensure proper operation of the pacemaker and 
the presence of 1: 1 conduction. The sham-operated controls were treated in identical 
fashion with the exception of rapid pacing. 11,14;30.31.34 Following 3 weeks of SVT or sham 
procedures, a terminal study was carried out in which LV function was examined using 
11 
echocardiography, and myocyte contractile function, extractable protein, protein 
composition, and cytoskeleton were studied. 
Left Ventricular Function 
The pigs were sedated with 10 mg of midazolam (Versed, Hoffman-La Roche, 
Inc., Nutley, NJ) and placed in a custom-designed sling which allowed the animal to rest 
comfortably. Bipolar limb electrocardiogram (ECG) leads were attached, and an ECG 
was continuously monitored. The pacemaker was deactivated (SVT group only), and, 
after a 30 minute stabilization period, LV function was assessed by echocardiography . 34-37 
Two-dimensional directed and M-mode echocardiographic recordings (3.5' MHz 
transducer, Aloka Co., LTD, Japan) were used to image the LV from a right parasternal 
approach. Measurements were made using the American Society of Echocardiography 
criteria. 38 Left ventricular dimensions and thickness were obtained for subsequent 
analysis, and LV fractional shortening was computed as: (end diastolic dimension - end 
systolic dimension)/end diastolic dimension, and was expressed as a percentage. 
Following LV function measurements, the pigs were anesthetized with isoflurane (0.5 %, 
1.5 l/min), and ventilated through a non-recirculating anesthesia circuit. The left carotid 
artery was exposed and a catheter with a fluid-filled lumen was advanced into the left 
ventricle. Pressures from the fluid-filled catheter were obtained using an externally 
calibrated transducer (Statham P23ID, Gould, Oxnard, CA) and a pressure amplifier 
(78304A, Hewlett Packard Corp., Andover, MA). The pressure waveform was 
simultaneously recorded with the ECG using a multichannel recorder (Western Graphtec, 
FWR3701,"Irvine, CA) at 50 mm/s.37 Using'LV end diastolic dimension (EDD), end 
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diastolic wall thickness (WTh) , and systolic blood pressure (SBP), peak systolic wall 
stress was calculated as: 136 x [(SBP x EDD)/(4 x WTh) x (1 + WThlEDD)].39 The 
heart was quickly extirpated and placed in an oxygenated Krebs solution (125 mM NaCI, 
2.5 mM KCI, 1.25 mM KH2P04, 1.25 mM MgS04-7H20, 15 mM NaHC03, 22 mM 
glucose; pH 7.5). The great vessels were removed at the aortic and pulmonary valves 
and the left ventricle was weighed and then prepared for myocyte isolation. 
Myocyte Isolation 
Left ventricular myocytes were isolated using established techniques. 14,30,36,37 The 
left circumflex coronary artery was cannulated, and the tissue was rinsed free of blood 
with 35 mL modified Kraft-Bruhe (KB) solution (80 mM KCl, 30 mM K2HP04 , 5 mM 
MgS04, 10 mM glucose, 5 mM Na2-adenosine triphosphate, 20 mM taurine, 5 mM 
creatine, 5 mM succinate, and 5 mM HEPES, supplemented with 5 mM nitrilotriacetic 
acid and 0.1 % salt-free bovine serum albumin (BSA». Collagenase (0.5 mg/ml, type 
II, 146 units/mg, Worthington, Freehold, NJ) was then added to 75 mL of the modified 
KB solution and the tissue was perfused with the collagenase solution for 35 minutes. 
The tissue was then minced into 2 mm sections and added to an oxygenated trituration 
solution of fresh KB solution containing 2% BSA, deoxyribonuclease II (DNase, 51 
Kunitz units/mL, type IV, Sigma, SL Louis, MO), 300 J-tM CaC12 and collagenase (0.5 
mg/mL). The tissue and trituration solution were transferred to a centrifuge tube and 
gently agitated. After 15 minutes, the supernatant was removed and filtered, and the 
cells were allowed to settle. The myocyte pellet was then resuspended in standard 
culture medium (Medium 199, Gibeo Laboratories, Grand Island, NY) containing 2 mM 
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Ca2+ for functional studies, or in Krebs for extractable protein studies. The number of 
myocytes was counted at 100X magnification using a hemocytometer (Reichert-Jung, 
Cambridge Instruments Inc., Buffalo, NY) and aliquots of isolated myocyte suspensions 
were prepared for further study. Myocytes were prepared for immunofluorescence 
examination as described in a following section. 
Isolated Myocyte Function 
Isolated myocyte function was examined as previously reported by this 
laboratory.36.37 Coverslips were coated with Matrigel (Collaborative Research Inc., 
Bedford, MA) and incubated at 37°C for one hour. Isolated myocytes (5 x 104 ceIls/mL) 
were plated onto the treated coverslips and incubated at 37°C. After one hour the 
coverslips were irrigated with culture medium to remove unattached myocytes. The 
coverslips containing attached isolated myocytes were placed in a thermostatically 
controlled chamber (37°C) used for imaging on an inverted microscope (Axiovert IM35, 
Zeiss Inc., Germany). The chamber contained a volume of 2.5 mL oxygenated culture 
medium and 2 stimulating platinum electrodes. A 20X long working distance Hoffmann 
Modulation Contrast objective (Modulation Optics Inc., Greenvale, NY) was used to 
image the myocytes, which were stimulated to contract by field stimulating the tissue 
chamber at 1 Hz (SI1, Grass Instruments, Quincy, MA). Myocyte motion signals were 
captured and input through an edge detector system (Crescent Electronics, Sandy, UT). 
The distance between the left and right myocyte edges was converted into a voltage 
signal, digitized, and input to a computer (80286; ZBV2526, Zenith Data Systems, St. 
Joseph, MI) for subsequent analysis. Parameters computed from the digitized contraction 
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profiles include percent shortening (%), velocity of shortening (p.m/ s), and velocity of 
relengthening (/lm/ s). 
Extractable Protein Studies 
In order to detennine the extractability of myocyte proteins with the development 
of SVT, myocyte suspensions (average 336,000 myocytes/mL) were mechanically 
disrupted using a hand-held, glass dounce homogenizer. Ten aliquots for each sample 
were homogenized and then centrifuged at 10,000 g for 10 minutes to yield a 
supernatant, which contained the extracted protein and was then transferred to another 
tube. Some aliquots were homogenized only, and not fractionated. The protein 
concentration of the supernatants and of the non-fractionated myocyte samples was 
detennined by a colorimetric assay, based on the method of Bradford (BioRad Protein 
Assay Dye Concentrate, BioRad, Rockville Center, NY). By dividing the protein 
concentrations by the total number of myocytes in the volume of suspension used (p,g/ p.L 
+ myocytes/ p.L), the amount of extractable protein per myocyte (ng/myocyte, from the 
supernatant) and the total amount of protein per myocyte (ng/myocyte, from the nOll-
fractionated myocyte samples) were calculated. The supernatants and non-fractionated 
myocyte samples were then lyophilized and the supernatants, whole myocyte samples, 
and pellets were resuspended in a potassium based buffer (1.1 M potassium iodide, 0.1 
M potassium phosphate monobasic, 100 IJ-M dithiothreitol, and 150 p,M 
phenylmethylsulfonyl fluoride (PMSF) , pH 7.4).40 The protein concentration of the 
samples was again determined in the method described above. Aliquots of known protein 
(5 p.g) for each sample were resuspended in Laemmli41 sample buffer with 150 J.tM 
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PMSF added, boiled for 5 minutes, and then set on ice for 5 minutes. After the addition 
of 2 p,L Pyronin Y dye (2 %, Sigma, St. Louis, MO), the samples were loaded onto 
16x20, 1.5 mm thick polyacrylamide gels (10-13% gradient). A molecular weight 
marker (Sigma, St. Louis, MO) was routinely loaded on each geL The gels were run 
for 16-18 hours at 4°C, silver stained (BioRad Silver Stain Plus, BioRad, Rockville 
Center, NY), and then dried. The gels were then scanned using SigmaScanlImage 
(Jandel Scientific, Corte Madera, CA). 
Immunofluorescence Labeling of Myocytes 
In order to examine the relative content and distribution of cytoskeletal proteins 
with SVT induced cardiomyopathy, the cytoarchitecture of isolated myocytes was 
examined using immunofluorescence techniques. Isolated myocytes were fixed in a 
buffer solution (65 mM PIPES, 25 roM HEPES, 10 mM EGTA, and 3 mM MgC12) 
containing 3.7% formaldehyde for 10 minutes at room temperature. Myocytes were then 
washed in this buffer and centrifuged onto standard microscope slides (Cytospin, Shandon 
Southern Products, Cheshire, England). Immediately prior to immunostaining, the 
myocytes were permeabilized with 0.05% Triton X-loo for 20 minutes at room 
temperature and then washed with phosphate buffered saline (PBS). Myocyte 
preparations were incubated with 10% horse serum for 2 hours and then incubated with 
the selective antisera (a-tubulin or J3-tubuIin) overnight at 4°C. All of the antisera were 
monoclonal mouse IgGl isotype (Sigma, St. Louis, MO), and have been used to detect 
tubulin from many organisms (for example, chicken, rat, bovine, and human tubulin). 
The dilution of antisera used was determined in preliminary dilution studies (1: 1000 for 
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a-tubulin, 1: 500 for l1-tubulin). Following the overnight incubation in the primary 
antisera, myocytes were washed vigorously with PBS and then incubated with a 1: 80 
dilution of horse anti-mouse fluorescein isothiocyanate-Iabeled secondary antibody 
(Sigma, St. Louis, MO) for 30 minutes at room temperature. The myocytes were then 
washed in PBS and covers lipped in a 1: 1 glycerol:PBS mounting media containing 1.0% 
1,4 diazabicyclo[2.2.2]octane (Sigma, St. Louis, MO). Myocytes were then examined 
on an inverted microscope (Axiovert IM35, Zeiss Inc., Gennany) equipped with 
epifluorescence illumination and a 50 W Hg light source. Using 40X and 60X Plan-
Neoflar objectives, photomicrographs were recorded using Kodak T max 400 film (Eastman 
Kodak Co., Rochester, NY, USA) at a fixed exposure time of 15 seconds. Controls for 
immunostaining included deletion of the primary antibody as well as the use of non-
immune sera in the protocols. In addition to routine fluorescence microscopic 
examination, the relative content and distribution of the myocyte cytoskeleton was 
examined using confocal scanning microscopy. Myocytes were imaged with a 63X Plan-
Neoflar objective (NA 1.25, Zeiss Inc., Germany) and laser excitation was induced at 
488 nM using a Biorad MRC-I000 confocal microscope (Biorad, Rockville Center, NY). 
Images were acquired at 1.0 Ilm increments through the myocyte and the digitized signals 
analyzed using image analysis software (Comos, Biorad, Rockville Center, NY). 
Data Analysis 
LV function, isolated myocyte function, and total and extractable myocyte protein 
were compared between the control and SVT groups using a pooled or a separate t-test 
(BMDP Statistical Software, Inc., Los Angeles, CA). In addition, linear regression 
17 
analysis was performed in order to examine the relationship between myocyte function 
(velocity of shortening, velocity of relengthening), LV function (LV fractional 
shortening), and LV geometry (LV end diastolic volume) and myocyte protein 
extractability (percent extractable protein per myocyte). Results are presented as 
means ± SEM and values of p < 0.05 were considered to be statistically significant. 
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Results 
All of the pigs subjected to 3 weeks of pacing supraventricular tachycardia (SVT) 
completed the protocol. At the end of the pacing period, all of the SVT pigs exhibited 
signs and symptoms of congestive heart failure such as dyspnea and ascites. 
Left Ventricular Mass and Function 
Indices of LV function for control and SVT induced cardiomyopathic pigs are 
shown in Table 1. With SVT induced cardiomyopathy, a significant increase in LV end-
diastolic dimension with significantly reduced fractional shortening and end-diastolic wall 
thickness was observed. SVT cardiomyopathy resulted in significantly increased peak 
systolic wall stress compared to the control group. Graphs comparing LV mass to body 
weight and mass to volume ratios from control and SVT cardiomyopathic pigs are shown 
in Figure 2. Despite the significant increase in wall stress, there was no change in LV 
mass with SVT induced cardiomyopathy when normalized to body weight. However, 
there was a significant decrease in the LV mass to volume ratio. This indicates that 
significant LV dilation occurred with no significant change in LV mass. Therefore, 
consistent with previous reports, chronic pacing-induced tachycardia produced a dilated 
cardiomyopathy with no hypertrophy. 11,14,17,29,31,39 
Isolated Myocyte Function 
Representative photomicrographs of myocytes isolated from control (n = 298 
myocytes) and SVT cardiomyopathic (n = 484 myocytes) left ventricles are shown in 
Figure 3. With SVT induced cardiomyopathy,' myocytes were significantly longer than 
Table 1 
Left Ventricular Function with 
Supraventricular Tachycardia Induced Dilated Cardiomyopathy 
Heart Rate (beats/minute) 
LV End Diastolic Dimension (cm) 
Fractional Shortening (%) 
End Diastolic Wall Thickness (cm) 
Peak Systolic Wall Stress (g/cm2) 
Sample size (n) 
All values presented as Mean + SEM. 








SVT: 3 weeks of supraventricular pacing; 240 bpm 
SVT 







































Figure 2. Graphs showing the left ventricular (LV) mass to body weight and mass to volume 
ratios following the development of supraventricular tachycardia (SVT) induced cardiomyopathy. 
While the LV mass to body weight ratio remained the same with SVT cardiomyopathy, the LV 
mass to volume ratio significantly decreased. This indicates that significant LV dilation occurred 
with no significant change in LV mass (hypertrophy). *p<O.05 vs Control (n = 7, for both 
groups) 
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control myocytes (170+1* vs 139+1 jlm, *p<O.05 compared to control). However, in 
previous studies, myocyte cross-sectional area has been shown to significantly decrease 
with the development of SVT induced cardiomyopathy (292 + 5* vs 363 + 811m2). 31,42 
Parameters of contractile function for control and SVT induced cardiomyopathic 
myocytes are shown in Figure 4. With the development of SVT induced 
cardiomyopathy, isolated myocyte percent shortening, velocity of shortening (rate of 
crossbridging), and velocity of relengthening (rate of active relaxation) significantly 
decreased. Therefore, consistent with past reports, changes in LV pump performance 
were associated with alterations in myocyte contractile function and active relaxation 
processes. 11,34,37 
Extractable Protein Studies 
The total amount of protein per myocyte was not significantly different with the 
development of SVT induced cardiomyopathy (4.06±O.47 vs 3.15+0.16 ng/myocyte, 
p=0.108, SVT compared to control, respectively, n = 7 for both groups). The amount 
of extractable protein per isolated myocyte is shown in Figure 5 (top). There was a 
significant increase in extractable protein per myocyte with the development of SVT 
induced cardiomyopathy compared to controls. However, the range of values obtained 
from SVT cardiomyopathic myocytes was far greater than the range of values from 
controls. Table 2 shows individual values obtained for the different samples of 
extractable protein for each group. These individual values were calculated from 
separately dounced aliquots of myocyte suspensions from each sample, and as many as 
four supernatants were analyzed for protein concentration, and therefore amount of 
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Figure 3. Representative phase contrast photomicrographs of control left ventricular (LV) 
myo ytes (left) and LV myocytes following chronic supraventricular tachycardia (SVT) induced 
cardiomyopathy (right). With SVT induced cardiomyopathy, myocytes were significantly longer 
than control myocytes (170± 1 * vs 139± 1 JLm), but with significantly reduced cross-sectional 
area (292±5* vs 363 ±8 JLm2, *p < 0.05 compared to control). (n = 298 for control myocytes, 
n = 484 for SVT myocytes) Original magnification: 200X. 
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Figure 4, Isolated myocyte function measurements. With the development of supraventricular 
. tachycardia (SVT) induced cardiomyopathy, isolated myocyte percent and velocity of shortening, 
as well as velocity of relengthening, significantly decreased. *p<O.05 vs Control (n = 298 for 
, control myocytes, n = 484 for SVT myocytes) 
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Figure 5. Scatterplot of extractable protein per isolated myocyte (top). There was a significant 
increase in extractable protein per myocyte with the development of supraventricular tachycardia 
(SVT) induced cardiomyopathy. Graph of percent extractable protein per isolated myocyte 
(extractable protein normalized to total myocyte protein, bottom). There was a significant 
increase in percent extractable protein per myocyte with SVT induced cardiomyopathy. 
*p<O.05 vs Control (n = 7, for both groups) 
Table 2 
Amount of Extractable Protein in Individual, Samples with 
Supraventricular Tachycardia Induced Dilated Cardiomyopathy 
Sample Control Control Control Control 
number 1216 0109 0126 0206 
1 0.61 0.49 0.51 0.81 
2 0.68 0.49 0.51 0.80 
3 0.62 0.50 0.52 0.77 
4 0.67 
MEAN 0.65 0.49 0.51 0.79 
+ SEM +0.02 +0.003 +0.003 +0.01 
Sample SVT SVT SVT SVT 
number 1205 1208 0124 0125 
1 2.45 2.55 1.11 0.77 
2 2.29 2.66 1.10 0.76 
3 2.54 2.58 1.03 0.71 
4 2.33 2.58 1.04 0.71 
MEAN 2.40 2.59 1.07 0.74 
+ SEM +0.06 +0.02 +0.02 +0.02 
SVT: 3 weeks of supraventricular pacing; 240 bpm 






























extractable protein, per sample. Each of the mean values for the samples has a very 
small SEM, thus showing that the values are accurate and the methods for obtaining these 
values are capable of being reproduced. In order to more carefully detennine if changes 
in protein extractability occurred within the myocyte with SVT cardiomyopathy, 
extractable protein was nonnalized to the amount of protein in the non-fractionated 
myocytes for the same sample, yielding percent extractable protein of total myocyte 
protein (Figure 5, bottom). Analysis revealed a significant increase in percent extractable 
protein per myocyte with SVT induced cardiomyopathy compared to controls. 
The relationship between myocyte protein extractability (percent extractable 
protein of total myocyte protein) and changes in LV geometry (LV end diastolic volume) 
is shown in Figure 6. Linear regression analysis indicated that there is a significant 
relationship between increasing extractable protein and LV geometry with the 
development of SVT induced dilated cardiomyopathy (r = 0.39, P = 0.016). The 
relationship between myocyte protein extractability (percent extractable protein) and 
myocyte contractile function (velocity of shortening) is shown in Figure 7. Linear 
regression analysis indicated that there is a significant negative relationship between 
increasing extractable protein and myocyte function with the development of SVT 
induced cardiomyopathy (r = 0.318, P = 0.036), Table 3 contains these values, as well 
as the correlational values of percent extractable protein to LV fractional shortening and 
myocyte velocity of relengthening, which were also significant. Therefore, changes in 
myocyte protein extractability can be correlated to the changes in LV geometry, as well 
as to the changes in L V and myocyte function. 
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Myocyte Percent Extractable Protein vs. 
Left Ventricular End Diastolic Volume 
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Figure 6. The relationship between left ventricular geometry (LV end diastolic volume) 
and myocyte protein extractability (percent extractable protein per myocyte) with the 
development of supraventricular tachycardia (SVT) induced cardiomyopathy. There 
is a significant relationship between extractable protein and changes in LV geometry 
(~ = 0.39, P = 0.016). 
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Figure 7. The relationship between myocyte contractile function (velocity of shortening) 
and myocyte protein extractabi lity (percent extractable protein per myocyte) with the 
development of supraventricular tachycardia (SVT) induced cardiomyopathy. There is 
a negative relationship between increasing extractable protein and myocyte contractile 
function (r2 = 0.318, P = 0.036). 
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Table 3 
Correlation Between Percent Extractable Protein and Indices of: Left Ventricular 
Function and Geometry and Myocyte Contractile Function 
29 
Percent Extracted Protein Percent Extracted Protein 
(rZ) (p) 
Myocyte Velocity of 0.32 0.036 
Shortening 
Myocyte Velocity of 0.29 0.049 
Relengthening 
L V Fractional Shortening 0.31 0.037 
L V End Diastolic 0.39 0.016 
Volume 
In the next series of experiments, whole myocytes, as well as extractable protein, 
were subjected to electrophoretic separation in order to examine whether any changes in 
the profile of proteins occurred with SVT cardiomyopathy. Similar to previous reports, 
there was no change in whole myocyte myosin heavy chain content with the development 
of SVT induced cardiomyopathy (34.91+1.07 vs 32.64±1.21 IOD, p=0.21, SVT 
compared to control, respectively).31 Representative SDS-PAGE (of 2 duplicate sets of 
gels, 4 sets of control and SVT samples each set of gels) of extractable proteins from 
control myocytes and myocytes following SVT induced cardiomyopathy are shown in 
Figure 8. Extractable protein was increased with SVT cardiomyopathy at the 114 and 
58 kD regions, as well as at a very high molecular weight (much greater than myosin). 
Immunofluorescence Localization of Tubulin 
In order to determine if changes in cytoskeletal proteins occurred with the 
development of SVT induced cardiomyopathy, the relative content and distribution of a-
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Figure 8. Representative SDS-PAGE of extractable protein from control myocytes and 
myocytes following supraventricular tachycardia (SVT) induced cardiomyopathy. Extractable 
protein was increased with SVT cardiomyopathy at the 114 and 58 kD regions. These molecular 
weights may correspond to dimeric and monomeric tubulin. An increase in extractable protein 
with SVT was also observed at a very high molecular weight which may correspond to titin. (4 
control and 4 SVT sample sets per set of gels, done in duplicate) 
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and l3-tubulin within control and SVT cardiomyopathic isolated myocytes was observed 
after the use of immunofluorescence techniques. Representative control (n = 15) and 
SVT cardiomyopathic (n = 12) myocytes stained for a-tubulin and imaged using 
confocal microscopy are shown in Figure 9. In control myocytes, strong staining for (X-
tubulin was observed in the perinuclear regions with a fine array of staining within the 
cytoplasm. This staining pattern for microtubules within the control myocytes with 
respect to a fine network and dense perinuclear regions is consistent with past reports. 25,43 
In SVT myocytes, the relative abundance of a-tubulin appeared significantly increased 
not only in the perinuclear regions, but throughout the myocyte; however, this technique 
is not quantitative, and therefore, absolute changes in the amount of a-tubulin cannot be 
determined from this method of immunostaining. Furthermore, in SVT myocytes, a-
tubulin appeared to be distributed in a linear array which was parallel to the long axis 
of the myocyte. Scanning laser confocal imaging for representative control (n = 12) and 
SVT (n = 16) myocytes following immunostaining for l3-tubulin is shown in Figure 10. 
The relative staining distribution of l3-tubulin in control myocytes was similar to that of 
a-tubulin. Specifically, there was strong perinuclear staining with a delicate meshwork 
of staining coursing through the cytoplasm. In SVT myocytes, the relative abundance 
of l3-tubulin appeared similar to control myocytes. However, with SVT cardiomyopathy, 
the fine tubular pattern of staining was replaced by a more coarse and linear array which 
was oriented to the long axis of the myocyte. Substitution of non-immune sera or 
preabsorption of the antisera abolished all of the immunofluorescent signal. 
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ALPHA TUBULIN LOCALIZATION IN CONTROL AND SVT MYOCYTES 
Figure 9. Representative left ventricular myocytes from control pigs (left) and from pigs 
following the development of supraventricular tachycardia (SVT) induced cardiomyopathy (right) 
after immunofluorescent staining for a-tubulin. In control myocytes (n = 15), a tortuous tubular 
network of positive staining was observed and was particularly strong in the perinuclear region. 
In SVT myocytes (n = 12), the relative fluorescence of a-tubulin was altered and appeared in 
a linear orientation throughout the myocyte. Magnification: 438X top, 1313X bottom 
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BETA-TUBULIN LOCALIZATION IN CONTROL AND SVT MYOCYTES 
Figure 10. Representative left ventricular myocytes from control pigs (left) and from pigs 
following the development of supraventricular tachycardia (SVT) induced cardiomyopathy (right) 
after immunofluorescent staining for l1-tubulin. In control myocytes (n = 12), the pattern of 
immunofluorescent staining for l1-tubulin was similar to the pattern observed with a-tubulin. 
A fine weave of positive staining occurred throughout the myocyte. In SVT myocytes (n = 16), 
the tortuous network of staining for l1-tubulin was replaced by a strong immunofluorescent 




Chronic supraventricular tachycardia (SVT) has been shown to cause LV dilation 
and dysfunction and neurohormonal activation, which is similar to the clinical spectrum 
of cardiomyopathic disease. 3,6,8-12 These changes in LV function are accompanied by 
increased wall stress with no concomitant change in LV mass. 11,12,14,15 Therefore, despite 
chemical and physical stimuli, the left ventricle does not hypertrophy and develops a 
dilated cardiomyopathy. 31 Furthermore, chronic pacing induced SVT has been shown to 
cause alterations in myocyte contractile function and geometry with associated changes 
in myocyte ultrastructure. 3,6,8-11,13,14 However, intracellular mechanisms responsible for 
the changes in LV and myocyte geometry and function which occur in this form of 
cardiomyopathic disease remain unknown. Thus the overall goal of this study was to 
examine potential cellular mechanisms that may be related to the changes in LV and 
myocyte geometry and function. 
Three important findings resulted from the present study. First, the development 
of SVT induced cardiomyopathy resulted in a significant increase in the amount of 
extractable myocyte protein, which may relate to a decrease in the crosslinking of 
myocyte proteins with SVT. Second, a positive correlation exists between myocyte 
extractable protein and changes in LV geometry, while a negative correlation exists 
between extractable protein and myocyte contractile function. Third, following 
electrophoretic separation, the extractable protein from SVT myocytes was increased at 
the 114 and 58 kD regions; these molecular weights may correspond to dimeric 
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(approximately 110 kD) and monomeric (approximately 55 leD) tubulin.24 An increase 
in extractable protein was also observed at a very high molecular weight, which may 
correspond to titin (2-3 MDa).22 The increase in banding seen in the molecular weight 
ranges of these proteins thus suggests that an increase in the extractability of these 
proteins occurs with the development of SVT. The possible alteration in tubulin 
extractability within SVT cardiomyopathic myocytes may correspond to the altered 
immunofluorescent staining for Ci- and J3-tubulin in SVT myocytes. Therefore, the 
findings from the present study suggest that alterations in myocyte protein extractability, 
extractable protein composition, and cytoarchitecture may be related to the depressed 
contractile performance in this form of cardiomyopathic disease. 
Past studies have shown that the development of SVT induced cardiomyopathy is 
accompanied by an increase in myocyte length, a reduction in myocyte cross-sectional 
area, and no associated changes in myosin heavy chain at the mRNA or the protein 
level. 29.31-33 The findings from these studies suggest that significant intracellular 
remodeling occurs with the development of SVT cardiomyopathy, which provides a 
structural basis for myocyte lengthening with no change in contractile protein content. 
A potential mechanism for the alterations in myocyte geometry with the development of 
SVT induced cardiomyopathy is changes in protein assembly and/or disassembly within 
the myocyte. Alterations in protein assembly may result in changes in protein 
crosslinking, and therefore, protein function and stability. 44 In the present study, the 
degree of protein crosslinking was correlated to amount of extractable protein on the 
premise that a protein which is not well bound into the cellular structure is more easily 
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extracted from the myocyte. With the development of SVT induced cardiomyopathy, 
myocyte extractable protein was significantly increased. Thus, SVT cardiomyopathic 
myocyte proteins may be less crosslinked. A possible explanation for the increase in 
extractable protein is an increase in the synthesis of soluble myocyte proteins. However, 
there was no significant increase in total myocyte protein with the development of SVT 
cardiomyopathy, and no noticeable changes in protein banding in the non-fractionated, 
whole myocyte samples which underwent electrophoresis, compared to control samples. 
Therefore, the increase in extractable protein can be attributed to a decrease in protein 
crosslinking and not increased total protein levels. 
While changes in myocyte protein extractability were seen with SVT, 
electrophoretic analysis did not reveal any changes in the extraction profile of myocyte 
contractile proteins. However, an increase in extracted protein was observed at the 
molecular weight ranges of dimeric and monomeric tubulin. Tubulin is the primary 
building block of microtubules, which function as structural and mobile elements in 
mitosis, intracellular transport, and the cytoskeleton. 24 Therefore, comparable to 
previous studies, there was no change in contractile proteins while cytoskeletal proteins 
may have been altered with the development of SVT cardiomyopathy. 31 
Active hypertrophying myocytes from rat and rabbit hearts have been shown, with 
immunofluorescent staining, to experience an increase in the numbers of microtubules 
streaming away from the nucleus towards the sarcoplasm. 26 Past studies have also shown 
that microtubule reorganization is related to the onset of the adaptational process of 
myocytes to volume overload which results in hypertrophy. 25 An increase in 
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microtubules, or tubulin, has also been associated with a decrease In myocyte 
contractility, in both the hypertrophied and the dilated cardiomyopathic state.25-27 ,31,45 
Experiments conducted in which microtubules were depolymerized have shown 
that they play a minor role in the direct maintenance of myocyte shape, since 
depolymerization of microtubules had no subsequent effect on myocyte shape. 26 The 
myofilament organization of the myocyte, rather than the microtubule network, appears 
to be responsible for the shape and structure of the myocyte. However, microtubules in 
an equilibrium of assembled and disassembled tubulin might influence the polymerization 
and/ or spatial organization of myofibrillar structure. 26 As stated previously, intracellular 
remodeling occurs with the development of SVT cardiomyopathy, causing reassembly of 
sarcomeres. Microtubules may playa role in sarcomere assembly and alignment, and 
the observed increase in tubulin in a pattern that is not consistent with nonnal cells 
suggests that the increase in tubulin is interfering in the normal assembly of sarcomeres. 
Also observed in SVT myocytes is an increase in tubulin along the long axis of the cell, 
corresponding to the increased length of the myocyte with the development of SVT 
cardiomyopathy. Therefore, with an increase in the extractability of tubulin, and an 
increase of microtubules along the length of the cell, microtubule function is probably 
disturbed. Due to the role microtubules play in cellular transport and in sarcomere 
registration, changes should occur in the post-translational processing of proteins, in 
protein assembly into the cellular structure, and, ultimately, in the function of the 
myocyte as a result of the potentially altered tubulin crosslinking with the development 
of SVT induced cardiomyopathy. 
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Previous reports have indicated that changes in the cytoskeletal architecture of 
myocytes may contribute to the depressed contractile function seen with the development 
of heart failure. 23,31,28,45 An increase in a very high molecular weight protein in the 
extractable protein from SVT cardiomyopathic myocytes, as seen with electrophoresis, 
suggests that another cytoskeletal protein which may be altered with the development of 
SVT cardiomyopathy is titin. Recent studies indicate that in disease states, such as 
Duchenne muscular dystrophy and Fukuyama type congenital muscular dystrophy, titin 
is degraded in myocytes. 46 Studies on human hearts with end-stage heart failure found 
significantly reduced amounts of titin and a structurally altered form of titin in skinned 
fibers, as well as reduced titin mRNA levels. 23 ,28 Titin is an integral component of the 
myosin filament and plays an important role in the regulation of both thick filament 
length and assembly.47 Titin acts to keep the thick filament centered within the 
sarcomere during tension development,48 thus maintaining an ordered sarcomere 
structure. Therefore, alterations in the amount and structure oftitin may be an important 
contributory mechanism in the depressed contractile performance seen with the 
development of SVT induced cardiomyopathy. 
A future study investigating and quantifying the levels and structure of a-tubulin, 




In summary, chronic supraventricular tachycardia (SVT) in animals has been 
shown to result in a dilated cardiomyopathy with symptoms similar to those seen in 
human cases of cardiomyopathic disease. Therefore, this model provides an opportunity 
to investigate the primary mechanisms which contribute to the development and 
progression of cardiomyopathic disease. The goal of the present study was to examine 
potential cellular mechanisms that may contribute to the changes in LV and myocyte 
geometry and function seen in this model of dilated cardiomyopathy. Extractable protein 
studies showed that the development of SVT induced cardiomyopathy resulted in a 
significant increase in the extractability of myocyte proteins, specifically in the 114 and 
58 kD ranges, and also at a very high molecular weight. These molecular weight ranges 
may correspond to dimeric and monomeric tubulin, and possibly titin. The increase in 
extractable protein is related to changes in LV geometry, as well as negatively related to 
myocyte contractile function. The potential increase in tubulin extractability may also be 
related to the altered pattern of u- and p-tubulin immunofluorescent 
staining seen with SVT cardiomyopathy. Due to the important functions of 
microtubules and titin within the myocyte, alterations In the structure 
and/or extractability of these proteins could be related to the decreased 
contractile performance seen with the development of SVT induced 
cardiomyopathy. Future studies investigating the relative levels and 
structures of a-tubulin, p-tubulin, and titin should be considered. 
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